انسولین دگلودک (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "انسولین دگلودک" in Persian language version.

refsWebsite

Global rank Persian rank

4^th place

5^th place

2^nd place

3,912^th place

779^th place

68^th place

179^th place

1^st place

11^th place

52^nd place

clincalc.com

"The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
"Insulin Degludec - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T (May 2007). "Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes". Diabetes, Obesity & Metabolism. 9 (3): 290–9. doi:10.1111/j.1463-1326.2006.00685.x. PMID 17391154. S2CID 23810204.
Haahr H, Heise T (September 2014). "A review of the pharmacological properties of insulin degludec and their clinical relevance". Clinical Pharmacokinetics. 53 (9): 787–800. doi:10.1007/s40262-014-0165-y. PMC 4156782. PMID 25179915.

CHMP (October 18, 2012), "Summary of opinion 1 (initial authorisation): Tresiba" (PDF), Pending EC decisions (PDF), آژانس دارویی اروپا, archived from the original (PDF) on 11 January 2017, retrieved November 6, 2012

Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T (May 2007). "Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes". Diabetes, Obesity & Metabolism. 9 (3): 290–9. doi:10.1111/j.1463-1326.2006.00685.x. PMID 17391154. S2CID 23810204.
Haahr H, Heise T (September 2014). "A review of the pharmacological properties of insulin degludec and their clinical relevance". Clinical Pharmacokinetics. 53 (9): 787–800. doi:10.1007/s40262-014-0165-y. PMC 4156782. PMID 25179915.

Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T (May 2007). "Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes". Diabetes, Obesity & Metabolism. 9 (3): 290–9. doi:10.1111/j.1463-1326.2006.00685.x. PMID 17391154. S2CID 23810204.

CHMP (October 18, 2012), "Summary of opinion 1 (initial authorisation): Tresiba" (PDF), Pending EC decisions (PDF), آژانس دارویی اروپا, archived from the original (PDF) on 11 January 2017, retrieved November 6, 2012